April 11, 2014

Genkyotex's GKT137831 Found to Reverse Fibrosis and Improve Survival in a Model of Persistent Lung Fibrosis

“Specifically, we were able to demonstrate that established fibrosis in lungs of aged mice is partially reversed by administration of GKT137831, a new NOX inhibitor from Genkyotex,” explained Victor J. Thannickal, MD, Professor of Medicine and Pathology, Director, Division of Pulmonary, Allergy, and Critical Care, University of Alabama at Birmingham.

UAB in the News

 
 
Back to Top